AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) was the target of unusually large options

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Mode

AbCellera Biologics Inc. (NASDAQ:ABCL) announced positive top-line Phase 2 results from its Phase 1/

AbCellera reports positive Phase 2 clinical trial results for ABCL635, a single-dose treatment for m

Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regul

AbCellera (ABCL), a Vancouver clinical-stage antibody biotech, rose 33.19% intraday after its experi

BWMN gained 55.1%, HZO rose 45.8%, ABCL gained 35.6%, SLN rose 34.3%, ACHR gained 19.5%, NESR gained

AbCellera Biologics NASDAQ: ABCL reported top-line four-week results from a Phase II trial of ABCL-6

Gainers Jin Medical International (NASDAQ:ZJYL) stock rose 70.7% to $3.67 during Monday's pre-m

[url="]AbCellera[/url] (Nasdaq: ABCL) today announced positive top-line results from the Phase 2 por

Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe

BKYI: -8% | BIO-key And Visualforma Win Contract To Strengthen Digital Identity Security For Portugu

AbCellera ‌said Monday its experimental menopause treatment significantly reduced the ​frequency and

Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Positive Top-Line Phase

Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's afte

Management to host a conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ETAbCellera (NASDA

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Announce Top-Line Results from

Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises t

Cantor Fitzgerald analyst Steve Seedhouse maintains AbCellera Biologics (NASDAQ:ABCL) with a Over

AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcript

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.18 per share versus the Zacks C

AbCellera Biologics NASDAQ: ABCL said it expects to report top-line data “very soon” from its Phase

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.18) per share which missed the an

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q2 2026 Business Results.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Collaboration with Verte

Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCel

/PRNewswire/ -- For years, the promise of artificial intelligence in drug discovery has been easy to

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2026 Fina

Does AbCellera Biologics Inc. (ABCL) have what it takes to be a top stock pick for momentum investor

Benchmark analyst Robert Wasserman upgrades AbCellera Biologics (NASDAQ:ABCL) from Hold to Buy an

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Lynn Seely to its Boa

Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their

Jazz Pharmaceuticals teams with AbCellera on cancer therapies as analysts maintain positive targets

The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in po

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the anal

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on AbCellera Biologics (NASDAQ:ABCL)

AbCellera (NASDAQ:ABCL) today announced that it will disclose interim results from the Phase 1 porti

Jones Trading analyst Debanjana Chatterjee initiates coverage on AbCellera Biologics (NASDAQ:ABCL

AbCellera Biologics shares jumped 9.3% after hours to $3.52 following an 83% earnings beat in Q4 202

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.03) per share which beat the anal

AbCellera (Nasdaq: ABCL) today announced that the first patients have been dosed in the Phase 2 port

AbCellera (Nasdaq: ABCL) today announced that it has entered into a settlement and patent license ag

Risk-off sentiment dominated Wall Street on Friday, with selling pressure in AI-linked names intensi